Abstract
The development of Genetically Engineered Mouse Models (GEMMs) has catalyzed tremendous progress in cancer research. However, it has been difficult to design adequate mouse models for high-grade serous carcinoma (HGSC), the most common and lethal form of ovarian cancer. The genetic complexity of the disease, as well as the recent appreciation that most HGSCs arise from the fallopian tube (FT) secretory epithelium rather than the ovarian surface epithelium, has stifled the development of robust GEMMs. In a recent issue of this journal, Zhai et al presented an elegant mouse model for ovarian cancer that uses Ovgp1 as an FT-specific promoter to inactivate Brca1, Trp53, Rb1, Nf1, and Pten. The authors showed that loss of these genes in the mouse FT epithelium can mimic the different stages of human HGSC tumorigenesis. Their robust model emphasizes the importance of considering both the cell of origin and tumor genetics in developing accurate model systems. They provide a useful tool for studying mechanisms of disease in vivo and for research into novel methods of prevention, early detection, and treatment of HGSC. Copyright © 2018 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
References
Apr 7, 2000·Carcinogenesis·K F RobyP F Terranova
Aug 31, 2002·Molecular Reproduction and Development·Ichiro MiyoshiNoriyuki Kasai
Jan 26, 2006·The American Journal of Surgical Pathology·Fabiola MedeirosChristopher P Crum
Jul 2, 2011·Nature·UNKNOWN Cancer Genome Atlas Research Network
Feb 15, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jaeyeon KimMartin M Matzuk
Dec 18, 2013·Cancer Cell·Ruth PeretsRonny Drapkin
Jan 30, 2014·International Journal of Cancer. Journal International Du Cancer·Paul H van der HorstLeen J Blok
Mar 22, 2014·The Journal of Pathology·Cheryl A Sherman-BaustPatrice J Morin
Oct 24, 2015·Nature Reviews. Cancer·David D BowtellFrances R Balkwill
Aug 18, 2016·Cancer Research·Josephine WaltonIain A McNeish
Oct 21, 2016·The Journal of Pathology·Rong WuKathleen R Cho
Nov 29, 2016·Gynecologic Oncology·Anthony N Karnezis, Kathleen R Cho
Nov 30, 2016·Current Opinion in Obstetrics & Gynecology·Paul T Kroeger, Ronny Drapkin
Jun 14, 2017·The Journal of Pathology·Yali ZhaiKathleen R Cho
Oct 25, 2017·Nature Communications·S Intidhar Labidi-GalyVictor E Velculescu
Citations
Nov 15, 2018·Cancers·Jaeyeon KimRobert C Bast
Jun 13, 2019·Biology of Reproduction·David P Cook, Barbara C Vanderhyden
Mar 29, 2019·Journal of Ovarian Research·Petr MullerBorivoj Vojtesek
Jun 5, 2020·PLoS Genetics·Olga KimJaeyeon Kim
Feb 2, 2020·Scientific Reports·Marcia de Almeida Monteiro Melo FerrazNucharin Songsasen
Nov 28, 2019·Nature Communications·Shuang ZhangBenjamin G Neel
Nov 8, 2020·Cancer Discovery·Sonia IyerRobert A Weinberg
Jan 16, 2020·Cell Reports·Eleni ManiatiFrances R Balkwill
Mar 22, 2020·Pharmacology & Therapeutics·Hunter D Reavis, Ronny Drapkin
May 1, 2021·Genome Medicine·Da PengPatrick Cahan
Jun 3, 2021·Cells·Monika KressinKlaus Strebhardt
Sep 16, 2020·Seminars in Cancer Biology·Olivia Le SauxS Intidhar Labidi-Galy